• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

拉莫三嗪控释制剂的体外-体内相关性研究。

In vitro-in vivo correlation of modified release dosage form of lamotrigine.

机构信息

Bioanalytical Laboratory, Torrent Pharmaceutical Ltd, Bhat, Gandhinagar-382428, Gujarat, India.

出版信息

Biopharm Drug Dispos. 2009 Dec;30(9):524-31. doi: 10.1002/bdd.688.

DOI:10.1002/bdd.688
PMID:19823969
Abstract

The plasma concentration profile of lamotrigine was predicted from the dissolution test data of the modified release 100 mg lamotrigine tablet by applying the in vitro-in vivo correlation (IVIVC). Three different release formulations (L-1, L-2 and L-3) and its profiles of in vitro data were generated in different dissolution media. Pharmacokinetics evaluation of these formulations was carried out in 12 healthy volunteers. In vitro-in vivo correlation was established from the generated dissolution and bioavailability data. A good correlation between the percentages dissolved vs absorbed (r2>0.989) was obtained using level A correlation. Evaluation of the internal predictability of level A correlation was calculated in terms of percent prediction error, which was found to be below 15%.

摘要

采用体外-体内相关性(IVIVC),从改良释放 100mg 拉莫三嗪片的溶出度试验数据预测拉莫三嗪的血浆浓度曲线。在不同的溶出介质中生成了三种不同的释放制剂(L-1、L-2 和 L-3)及其体外数据的曲线。对这些制剂进行了 12 名健康志愿者的药代动力学评估。从生成的溶出度和生物利用度数据中建立了体外-体内相关性。使用级别 A 相关性获得了溶解百分比与吸收百分比之间的良好相关性(r2>0.989)。通过预测误差百分比来计算级别 A 相关性的内部预测能力的评估,发现预测误差百分比低于 15%。

相似文献

1
In vitro-in vivo correlation of modified release dosage form of lamotrigine.拉莫三嗪控释制剂的体外-体内相关性研究。
Biopharm Drug Dispos. 2009 Dec;30(9):524-31. doi: 10.1002/bdd.688.
2
In vivo biopharmaceutical characterisation of a new formulation containing the antiepileptic drug lamotrigine in comparison to plain and dispersible/chewable lamotrigine tablets.
Arzneimittelforschung. 2005;55(6):307-11. doi: 10.1055/s-0031-1296864.
3
In-vitro and in-vivo correlation for two gliclazide extended-release tablets.两种格列齐特缓释片的体外与体内相关性
J Pharm Pharmacol. 2007 Jul;59(7):971-6. doi: 10.1211/jpp.59.7.0009.
4
Once-a-day extended-release dosage form of divalproex sodium III: development and validation of a Level A in vitro-in vivo correlation (IVIVC).丙戊酸镁缓释片一日一次剂型III:A级体外-体内相关性(IVIVC)的开发与验证
J Pharm Sci. 2005 Sep;94(9):1949-56. doi: 10.1002/jps.20387.
5
Development of a Level A in Vitro-in Vivo Correlation for Veliparib (ABT-888) Extended Release Tablet Formulation.开发用于维利帕尼(ABT-888)延长释放片剂制剂的 A 级体外-体内相关性。
Pharm Res. 2017 Jun;34(6):1187-1192. doi: 10.1007/s11095-017-2133-3. Epub 2017 Feb 27.
6
Biopharmaceutical characterization of carbamazepine immediate release tablets. In vitro-in vivo comparison.卡马西平速释片的生物制药特性。体外-体内比较。
Arzneimittelforschung. 2007;57(8):511-6. doi: 10.1055/s-0031-1296640.
7
Steady-state pharmacokinetics and bioavailability of immediate-release and extended-release formulations of lamotrigine in elderly epilepsy patients: Use of stable isotope methodology.拉莫三嗪速释和缓释制剂在老年癫痫患者中的稳态药代动力学和生物利用度:稳定同位素方法的应用
J Clin Pharmacol. 2015 Oct;55(10):1101-8. doi: 10.1002/jcph.522. Epub 2015 Aug 18.
8
In vitro-in vivo correlations for three different commercial immediate-release indapamide tablets.三种不同市售速释吲达帕胺片的体外-体内相关性
Drug Dev Ind Pharm. 2014 Dec;40(12):1670-6. doi: 10.3109/03639045.2013.842577. Epub 2013 Oct 8.
9
In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.健康志愿者中,来自双峰释放制剂的哌甲酯的体外溶出和体内口服吸收情况。
Biopharm Drug Dispos. 2004 Mar;25(2):91-8. doi: 10.1002/bdd.390.
10
Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data.利用尿药代动力学数据建立氯化钾缓释片体外-体内相关性
Pharm Res. 2017 Jul;34(7):1527-1533. doi: 10.1007/s11095-017-2179-2. Epub 2017 May 16.

引用本文的文献

1
Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste.灰黄霉素环糊精基纳米海绵作为儿科口服液剂型的制剂与评价,以提高生物利用度并掩盖苦味。
Saudi Pharm J. 2020 Mar;28(3):349-361. doi: 10.1016/j.jsps.2020.01.016. Epub 2020 Feb 3.
2
Use of the Biopharmaceutics Drug Disposition Classification System (BDDCS) to Help Predict the Occurrence of Idiosyncratic Cutaneous Adverse Drug Reactions Associated with Antiepileptic Drug Usage.使用生物药剂学药物处置分类系统(BDDCS)来帮助预测与抗癫痫药物使用相关的特发性皮肤药物不良反应的发生情况。
AAPS J. 2016 May;18(3):757-66. doi: 10.1208/s12248-016-9898-x. Epub 2016 Mar 7.
3
Enhancement of Solubility of Lamotrigine by Solid Dispersion and Development of Orally Disintegrating Tablets Using 3(2) Full Factorial Design.
通过固体分散体提高拉莫三嗪的溶解度以及采用3(2)全因子设计开发口腔崩解片
J Pharm (Cairo). 2015;2015:828453. doi: 10.1155/2015/828453. Epub 2015 Oct 27.
4
Improvement of physicochemical properties of an antiepileptic drug by salt engineering.通过盐工程改善抗癫痫药物的理化性质。
AAPS PharmSciTech. 2012 Sep;13(3):793-801. doi: 10.1208/s12249-012-9800-9. Epub 2012 May 17.
5
Comparison of dissolution profiles and serum concentrations of two lamotrigine tablet formulations.两种拉莫三嗪片剂制剂的溶出曲线和血清浓度比较。
Drugs R D. 2011;11(1):53-60. doi: 10.2165/11588260-000000000-00000.